BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
This procurement was divided into 2 lots, each awarded separately.
Lots
2
Combined Lot Value
£32,973,683
Lot
Value
Status
Lot 2
Natalizumab Solution for Infusion Vials and Injection Pre-filled Syringes
Feb 2024 – Apr 2025
£12,721,376
active
Lot 1
Teriflunomide Tablets, Dimethyl Fumarate Gastro-resistant Capsules, and Fingolimod Capsules
Feb 2024 – Apr 2025
£20,252,307
active
Award criteria
Weightings from the notice, applied to every lot.
Technical (Supply Chain)5%
Price95%
Key Dates
Published
3 November 2023
Tender Open
-
Tender Deadline
4 December 2023
Award Date
-
Contract Start
-
Contract End
-
Planned term
6 February 2024 – 30 April 2025
Extension option
The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-three (33) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
Procurement Details
Method
Open — any supplier may bid
Method Details
Open procedure
Route to market
Framework set up
Main category
Goods
Category
–
Delivery location
UKM
Open under
WTO Government Procurement Agreement
Buyer Reference
ocds-r6ebe6-0000749027
Legal Basis
Public Contracts Regulations 2015 (EU Directive 2014/24)